<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Healthcare Investment Strategy | Defensive & Opportunistic</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@700&family=Lato:wght@400;700&display=swap" rel="stylesheet">
    <style>
        .card-hover {
            transition: transform 0.3s ease-in-out, box-shadow 0.3s ease-in-out;
        }
        .card-hover:hover {
            transform: translateY(-8px);
            box-shadow: 0 10px 20px rgba(0,0,0,0.08);
        }
        .scenario-btn {
            transition: all 0.2s ease-in-out;
        }
        .scenario-btn.active {
            background-color: #0A2540; /* primary */
            color: white;
            box-shadow: 0 4px 14px 0 rgb(0 0 0 / 10%);
        }
        .scenario-btn:not(.active) {
             background-color: #F6F9FC; /* accent */
             color: #0A2540; /* primary */
        }
        .performance-summary {
            font-size: 0.9rem;
            line-height: 1.5;
        }
        .positive-driver {
            color: #16a34a; /* green-600 */
        }
        .negative-driver {
            color: #dc2626; /* red-600 */
        }
    </style>
    <script>
        tailwind.config = {
            theme: {
                extend: {
                    colors: {
                        primary: '#0A2540',
                        secondary: '#3C6FD6',
                        accent: '#F6F9FC',
                        'mine-shaft': '#333333',
                    },
                    fontFamily: {
                        heading: ['Montserrat', 'sans-serif'],
                        body: ['Lato', 'sans-serif'],
                    }
                }
            }
        }
    </script>
</head>
<body class="bg-white font-body text-mine-shaft">

    <!-- Navigation Bar -->
    <nav class="bg-primary text-white py-4 shadow-lg">
        <div class="container mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex items-center justify-between">
                <a href="#" class="font-heading text-xl font-bold hover:text-accent transition-colors">
                    ‚Üê Back to Home
                </a>
                <div class="text-sm text-gray-300">Investment Strategy</div>
            </div>
        </div>
    </nav>

    <div class="container mx-auto px-4 sm:px-6 lg:px-8 py-12 sm:py-16">

        <!-- Header Section -->
        <header class="text-center mb-16">
            <h1 class="font-heading text-4xl sm:text-5xl lg:text-6xl font-bold text-primary mb-4">
                The Health Care Thematic ‚öïÔ∏è
            </h1>
            <p class="max-w-3xl mx-auto text-lg text-gray-600">
                A defensive and opportunistic thesis capitalizing on the dual mandate of an aging population and a technological revolution in care delivery.
            </p>
        </header>

        <!-- High-Level Strategy & Rationale Section -->
        <section class="my-16 p-8 md:p-12 bg-accent rounded-2xl">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-8">Our High-Level Strategy & Rationale</h2>
                <div class="space-y-4 text-gray-700">
                    <p>The core thesis is built on the unavoidable challenge from two interlocking trends: a structural demographic shift to an older population and a concurrent rise in chronic diseases. This dual mandate creates a two-sided opportunity, positioning Health Care as both a defensive necessity and a hub of opportunistic innovation.</p>
                    <ul class="list-disc list-inside space-y-2 pl-4">
                        <li><strong class="text-secondary">Defensive Demand Floor:</strong> The world's aging population creates predictable, non-cyclical, and inelastic demand for medical products and services, making the sector resilient to economic downturns.</li>
                        <li><strong class="text-secondary">Opportunistic Innovation Catalyst:</strong> The rising cost burden from chronic disease creates urgent, system-wide demand for technologies that improve efficiency and outcomes, accelerating the adoption of innovation.</li>
                    </ul>
                    <div class="pt-6 mt-6 border-t border-gray-300">
                        <h3 class="font-heading text-xl font-bold text-primary mb-3">Timelines & Justification</h3>
                        <p>A <strong class="text-primary">7- to 10-year investment horizon</strong> is justified by the durable, multi-decade nature of the core demographic drivers. This timeframe is necessary to capture the full value-creation arc of transformative healthcare technologies, which involves long cycles of R&D, regulatory approval, and market adoption.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- The "Core + Explore" Strategy Section -->
        <section class="my-16">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-12">The "Core + Explore" Strategy: Balancing Stability & Growth</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8 text-center">
                    <!-- Pillar 1: Core Holdings -->
                    <div class="bg-white p-8 rounded-2xl border border-gray-200 card-hover">
                        <div class="flex items-center justify-center h-16 w-16 mx-auto mb-4 rounded-full bg-secondary/10 text-secondary">
                            <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" fill="currentColor" viewBox="0 0 16 16"><path d="M8.5 5.034a1.5 1.5 0 0 0-1 0L1 8.293V14.5A1.5 1.5 0 0 0 2.5 16h11a1.5 1.5 0 0 0 1.5-1.5V8.293L8.5 5.034zM15 7.093l-6-5.25L3 7.093V6.25a.5.5 0 0 1 .5-.5h1a.5.5 0 0 1 .5.5v.417L8.5 3.5 14 7.667V6.75a.5.5 0 0 1 .5-.5h1a.5.5 0 0 1 .5.5v.343z"/></svg>
                        </div>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Core Holdings</h3>
                        <p class="text-secondary font-bold text-lg mb-3">Stability & Defensive Growth</p>
                        <p class="text-gray-600">The portfolio's foundation is built on stable, profitable, wide-moat leaders. These companies provide defensive characteristics and are established players in their respective markets.</p>
                    </div>
                    <!-- Pillar 2: Explore Holdings -->
                    <div class="bg-white p-8 rounded-2xl border border-gray-200 card-hover">
                        <div class="flex items-center justify-center h-16 w-16 mx-auto mb-4 rounded-full bg-secondary/10 text-secondary">
                             <svg xmlns="http://www.w3.org/2000/svg" width="32" height="32" fill="currentColor" class="bi bi-rocket-takeoff" viewBox="0 0 16 16"><path d="M9.752 6.136a.5.5 0 0 0-.502.864l1.348.778-1.348.779a.5.5 0 0 0 .502.864l2.5-1.444a.5.5 0 0 0 0-.864l-2.5-1.444z"/><path d="M12.17 9.45c.17-.18.32-.37.44-.57l.01-.02a1.89 1.89 0 0 0 .23-1.02c0-.44-.13-.85-.36-1.2l-.02-.03a1.89 1.89 0 0 0-1.02-.83l-.03-.01a1.89 1.89 0 0 0-1.23.07c-.3.12-.56.3-.77.51l-.02.02a1.89 1.89 0 0 0-.57.44l-.02.01c-.18.17-.37.32-.57.44l-.02.01a1.89 1.89 0 0 0-1.02.23c-.44 0-.85.13-1.2.36l-.03.02a1.89 1.89 0 0 0-.83 1.02l-.01.03a1.89 1.89 0 0 0 .07 1.23c.12.3.3.56.51.77l.02.02a1.89 1.89 0 0 0 .44.57l.01.02c.17.18.32.37.44.57l.01.02a1.89 1.89 0 0 0 1.02.23c.44 0 .85-.13 1.2-.36l.03-.02a1.89 1.89 0 0 0 .83-1.02l.01-.03c.04-.31.04-.63-.07-1.23a1.89 1.89 0 0 0-.51-.77l-.02-.02a1.89 1.89 0 0 0-.44-.57zM8 15a.5.5 0 0 0 .5-.5V12.723c1.37-.253 2.622-.89 3.652-1.826.353-.32.69-.67.993-1.028C14.13 8.565 14.5 6.98 14.5 5.5c0-2.346-2.112-4.25-4.5-4.25S5.5 3.154 5.5 5.5c0 1.48.37 3.064 1.355 4.369.293.357.63.707.983 1.028 1.04 1.04 2.382 1.66 3.662 1.826V14.5a.5.5 0 0 0 .5.5zM8 2a3.5 3.5 0 0 1 3.5 3.5c0 .966-.413 2.185-1.158 3.328-.246.38-.523.74-.82 1.062-.29.313-.61.593-.952.83C7.32 11.69 6.165 12 5.5 12c-.966 0-2.185-.413-3.328-1.158-.38-.246-.74-.523-1.062-.82-.313-.29-.593-.61-.83-.952C-.69 7.68 0 6.515 0 5.5 0 3.015 2.015 1 4.5 1c.966 0 2.185.413 3.328 1.158.246.38.523.74.82 1.062.29.313.61.593.952.83.65-.66 1.191-1.24 1.58 1.745.32.42.54.82.68 1.18.14.36.22.7.22 1.02 0 .32-.08.66-.22 1.02-.14.36-.36.76-.68 1.18-.39.504-.93 1.085-1.58 1.745-.342.237-.662.517-.952.83-.297.322-.574.682-.82 1.062C9.685 13.087 8.466 13.5 7.5 13.5c-.966 0-2.185-.413-3.328-1.158-.38-.246-.74-.523-1.062-.82-.313-.29-.593-.61-.83-.952C1.31 9.82 1.5 8.655 1.5 7.5c0-.966.413-2.185 1.158-3.328.246-.38-.523.74-.82-1.062.29-.313.61-.593.952-.83.65-.66 1.191-1.24 1.58-1.745.32-.42.54.82.68 1.18.14.36.22.7.22 1.02 0 .32-.08.66-.22 1.02-.14.36-.36.76-.68 1.18-.39.504-.93 1.085-1.58 1.745-.342.237-.662.517-.952.83-.297.322-.574.682-.82 1.062C3.315 10.913 2.034 11.5 1 11.5c-.966 0-2.185-.413-3.328-1.158-.38-.246-.74-.523-1.062-.82-.313-.29-.593-.61-.83-.952C-3.69 8.68-4.5 7.515-4.5 6.5c0-2.485 2.015-4.5 4.5-4.5s4.5 2.015 4.5 4.5z"/></svg>
                        </div>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Explore Holdings</h3>
                        <p class="text-secondary font-bold text-lg mb-3">Disruption & Opportunistic Growth</p>
                        <p class="text-gray-600">Higher-risk, higher-reward investments in disruptive technologies with greater growth potential. These positions target outsized returns from emerging, high-growth markets.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- Suggested Asset Allocation Section -->
        <section class="my-16">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-10">Suggested Investment Candidates</h2>
                <div class="overflow-x-auto bg-white rounded-2xl border border-gray-200">
                    <table class="w-full text-left">
                        <thead class="bg-accent">
                            <tr>
                                <th class="p-4 sm:p-6 text-sm font-bold text-primary tracking-wider">Investment</th>
                                <th class="p-4 sm:p-6 text-sm font-bold text-primary tracking-wider">Ticker</th>
                                <th class="p-4 sm:p-6 text-sm font-bold text-primary tracking-wider">Category</th>
                                <th class="p-4 sm:p-6 text-sm font-bold text-primary tracking-wider">Modality</th>
                            </tr>
                        </thead>
                        <tbody class="divide-y divide-gray-200">
                            <tr>
                                <td class="p-4 sm:p-6 font-bold text-primary">Vertex Pharmaceuticals</td>
                                <td class="p-4 sm:p-6 text-gray-600">NASDAQ:VRTX</td>
                                <td class="p-4 sm:p-6 text-gray-600"><span class="inline-block bg-secondary/10 text-secondary px-2 py-1 text-xs font-bold rounded-full">Core</span></td>
                                <td class="p-4 sm:p-6 text-gray-800">Biopharmaceuticals</td>
                            </tr>
                             <tr>
                                <td class="p-4 sm:p-6 font-bold text-primary">Intuitive Surgical</td>
                                <td class="p-4 sm:p-6 text-gray-600">NASDAQ:ISRG</td>
                                <td class="p-4 sm:p-6 text-gray-600"><span class="inline-block bg-secondary/10 text-secondary px-2 py-1 text-xs font-bold rounded-full">Core</span></td>
                                <td class="p-4 sm:p-6 text-gray-800">MedTech & Diagnostics</td>
                            </tr>
                            <tr>
                                <td class="p-4 sm:p-6 font-bold text-primary">Guardant Health</td>
                                <td class="p-4 sm:p-6 text-gray-600">NASDAQ:GH</td>
                                <td class="p-4 sm:p-6 text-gray-600"><span class="inline-block bg-green-600/10 text-green-700 px-2 py-1 text-xs font-bold rounded-full">Explore</span></td>
                                <td class="p-4 sm:p-6 text-gray-800">MedTech & Diagnostics</td>
                            </tr>
                             <tr>
                                <td class="p-4 sm:p-6 font-bold text-primary">Teladoc Health</td>
                                <td class="p-4 sm:p-6 text-gray-600">NYSE:TDOC</td>
                                <td class="p-4 sm:p-6 text-gray-600"><span class="inline-block bg-green-600/10 text-green-700 px-2 py-1 text-xs font-bold rounded-full">Explore</span></td>
                                <td class="p-4 sm:p-6 text-gray-800">Digital Health</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
        </section>


        <!-- Prime Investment Candidates Section -->
        <section class="my-16">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-12">Prime Investment Candidates</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div class="bg-accent p-8 rounded-2xl border border-gray-200 card-hover">
                        <span class="inline-block bg-secondary text-white text-sm font-bold px-3 py-1 rounded-full mb-4">Core Holding</span>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Vertex Pharmaceuticals (VRTX)</h3>
                        <p class="text-gray-600 mb-4 italic">Leader in precision small molecules & gene editing.</p>
                        <p class="font-bold text-primary">Investment Thesis:</p>
                        <p class="text-gray-600 text-sm">A best-in-class investment offering a rare combination of a highly profitable, durable core franchise in cystic fibrosis that provides defensive cash flow, coupled with multiple high-potential "shots-on-goal" in new markets like gene editing and pain. Its proven scientific leadership, pristine balance sheet, and world-class execution create a de-risked profile for long-term appreciation.</p>
                    </div>

                    <div class="bg-accent p-8 rounded-2xl border border-gray-200 card-hover">
                        <span class="inline-block bg-secondary text-white text-sm font-bold px-3 py-1 rounded-full mb-4">Core Holding</span>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Intuitive Surgical (ISRG)</h3>
                        <p class="text-gray-600 mb-4 italic">The entrenched incumbent in robotic-assisted surgery.</p>
                        <p class="font-bold text-primary">Investment Thesis:</p>
                        <p class="text-gray-600 text-sm">The dominant, highly profitable leader in the large and underpenetrated market for robotic surgery. Its formidable moat‚Äîbuilt on proprietary technology, high customer switching costs, and a powerful recurring revenue model‚Äîmakes it a core, long-term holding. Benefits directly from the system's drive for better clinical outcomes and greater efficiency.</p>
                    </div>

                    <div class="bg-accent p-8 rounded-2xl border border-gray-200 card-hover">
                        <span class="inline-block bg-green-600 text-white text-sm font-bold px-3 py-1 rounded-full mb-4">Explore Pick</span>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Guardant Health (GH)</h3>
                        <p class="text-gray-600 mb-4 italic">A pioneer in liquid biopsy diagnostics for oncology.</p>
                        <p class="font-bold text-primary">Investment Thesis:</p>
                        <p class="text-gray-600 text-sm">A pure-play leader in the disruptive field of liquid biopsy, poised to transform how cancer is detected, treated, and monitored. Strong revenue growth, improving margins, and a massive market expansion into early-stage screening present a compelling high-growth, higher-risk opportunity. A direct play on the shift toward data-driven, non-invasive, personalized oncology.</p>
                    </div>
                    
                     <div class="bg-accent p-8 rounded-2xl border border-gray-200 card-hover">
                        <span class="inline-block bg-green-600 text-white text-sm font-bold px-3 py-1 rounded-full mb-4">Explore Pick</span>
                        <h3 class="font-heading text-2xl font-bold text-primary mb-2">Teladoc Health (TDOC)</h3>
                        <p class="text-gray-600 mb-4 italic">The scaled global player in virtual care delivery.</p>
                        <p class="font-bold text-primary">Investment Thesis:</p>
                        <p class="text-gray-600 text-sm">A value-oriented, potential turnaround investment on the powerful secular trend of virtual care. As the market leader by scale, it is positioned to benefit from the long-term shift of healthcare to digital platforms. Thesis is contingent on the new management team's ability to re-accelerate growth and demonstrate a clear path to sustained profitability.</p>
                    </div>
                </div>
            </div>
        </section>
        
        <!-- Predicted Performance Section -->
        <section class="my-16">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-4">Predicted Performance Scenarios</h2>
                <p class="text-center text-gray-600 mb-10 max-w-3xl mx-auto">Select a market scenario to view the projected performance drivers and underlying assumptions over a 7-year horizon.</p>
                
                <div id="scenario-controls" class="flex justify-center items-center gap-2 md:gap-4 mb-8">
                    <button data-scenario="bear" class="scenario-btn font-bold py-2 px-4 md:py-3 md:px-6 rounded-full">üêª Bear Case</button>
                    <button data-scenario="neutral" class="scenario-btn font-bold py-2 px-4 md:py-3 md:px-6 rounded-full active">üòê Neutral Case</button>
                    <button data-scenario="bull" class="scenario-btn font-bold py-2 px-4 md:py-3 md:px-6 rounded-full">üêÇ Bull Case</button>
                </div>
                
                <div id="scenario-descriptions" class="my-8 max-w-4xl mx-auto bg-accent p-6 rounded-2xl border border-gray-200">
                    <div id="desc-bear" class="scenario-desc hidden text-left">
                        <h4 class="font-heading text-lg font-bold text-red-700 mb-2">The Bear Scenario: "Payer Revolt & Tech Stagnation" (25% Probability)</h4>
                        <div class="text-sm text-gray-600 space-y-3">
                            <p><strong class="text-primary block mb-1">Assumptions:</strong> Governments and insurers enact aggressive price controls, severely restricting reimbursement for novel technologies. Key technological promises fail to materialize (e.g., gene therapies encounter safety issues). The market becomes commoditized as low-cost competitors erode margins in robotics and digital health. The U.S. government passes significant negative drug pricing legislation and CMS issues negative coverage decisions for key screening tests.</p>
                        </div>
                    </div>
                    <div id="desc-neutral" class="scenario-desc text-left">
                        <h4 class="font-heading text-lg font-bold text-primary mb-2">The Neutral Scenario: "Incremental Innovation & Adoption" (50% Probability)</h4>
                        <div class="text-sm text-gray-600 space-y-3">
                           <p><strong class="text-primary block mb-1">Assumptions:</strong> The current market trajectory continues with steady, mid-to-high single-digit growth driven by demographic tailwinds. Innovative companies with strong clinical data gain market share and secure favorable reimbursement. The shift to value-based care proceeds at a gradual pace. Profitability remains a challenge in digital health, leading to consolidation. Healthcare spending continues to outpace global GDP.</p>
                        </div>
                    </div>
                    <div id="desc-bull" class="scenario-desc hidden text-left">
                        <h4 class="font-heading text-lg font-bold text-green-700 mb-2">The Bull Scenario: "The 5P Revolution" (25% Probability)</h4>
                        <div class="text-sm text-gray-600 space-y-3">
                            <p><strong class="text-primary block mb-1">Assumptions:</strong> Technological convergence accelerates, ushering in a paradigm shift toward "Predictive, Preventative, Proactive, Personalised, and Precise" healthcare. Cell and gene therapies prove to be durable cures. Liquid biopsy screening becomes the standard of care for multiple cancers. AI-powered, virtual-first care platforms become the default "front door" to the healthcare system, driving massive efficiency gains and cost savings.</p>
                        </div>
                    </div>
                </div>


                <div class="grid grid-cols-1 md:grid-cols-2 gap-8 mt-12">
                    <!-- VRTX Performance Card -->
                    <div class="bg-accent p-6 md:p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-4">Vertex (VRTX) Drivers</h3>
                        <div id="vrtx-drivers" class="performance-summary"></div>
                        <div class="w-full mt-6">
                            <p class="text-xs text-gray-500 mb-2 font-bold tracking-wider uppercase">Projected Year-on-Year Return (%)</p>
                            <div class="grid grid-cols-4 md:grid-cols-7 gap-2 text-center text-xs">
                                <div><p class="font-bold text-gray-600">2025</p><p id="vrtx-2025" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2026</p><p id="vrtx-2026" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2027</p><p id="vrtx-2027" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2028</p><p id="vrtx-2028" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2029</p><p id="vrtx-2029" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2030</p><p id="vrtx-2030" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2031</p><p id="vrtx-2031" class="font-mono mt-1 font-bold"></p></div>
                            </div>
                        </div>
                    </div>

                    <!-- ISRG Performance Card -->
                    <div class="bg-accent p-6 md:p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-4">Intuitive Surgical (ISRG) Drivers</h3>
                        <div id="isrg-drivers" class="performance-summary"></div>
                        <div class="w-full mt-6">
                            <p class="text-xs text-gray-500 mb-2 font-bold tracking-wider uppercase">Projected Year-on-Year Return (%)</p>
                            <div class="grid grid-cols-4 md:grid-cols-7 gap-2 text-center text-xs">
                                <div><p class="font-bold text-gray-600">2025</p><p id="isrg-2025" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2026</p><p id="isrg-2026" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2027</p><p id="isrg-2027" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2028</p><p id="isrg-2028" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2029</p><p id="isrg-2029" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2030</p><p id="isrg-2030" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2031</p><p id="isrg-2031" class="font-mono mt-1 font-bold"></p></div>
                            </div>
                        </div>
                    </div>

                    <!-- GH Performance Card -->
                    <div class="bg-accent p-6 md:p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-4">Guardant Health (GH) Drivers</h3>
                        <div id="gh-drivers" class="performance-summary"></div>
                        <div class="w-full mt-6">
                            <p class="text-xs text-gray-500 mb-2 font-bold tracking-wider uppercase">Projected Year-on-Year Return (%)</p>
                            <div class="grid grid-cols-4 md:grid-cols-7 gap-2 text-center text-xs">
                                <div><p class="font-bold text-gray-600">2025</p><p id="gh-2025" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2026</p><p id="gh-2026" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2027</p><p id="gh-2027" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2028</p><p id="gh-2028" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2029</p><p id="gh-2029" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2030</p><p id="gh-2030" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2031</p><p id="gh-2031" class="font-mono mt-1 font-bold"></p></div>
                            </div>
                        </div>
                    </div>
                    
                    <!-- TDOC Performance Card -->
                    <div class="bg-accent p-6 md:p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-4">Teladoc Health (TDOC) Drivers</h3>
                        <div id="tdoc-drivers" class="performance-summary"></div>
                        <div class="w-full mt-6">
                            <p class="text-xs text-gray-500 mb-2 font-bold tracking-wider uppercase">Projected Year-on-Year Return (%)</p>
                            <div class="grid grid-cols-4 md:grid-cols-7 gap-2 text-center text-xs">
                                <div><p class="font-bold text-gray-600">2025</p><p id="tdoc-2025" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2026</p><p id="tdoc-2026" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2027</p><p id="tdoc-2027" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2028</p><p id="tdoc-2028" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2029</p><p id="tdoc-2029" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2030</p><p id="tdoc-2030" class="font-mono mt-1 font-bold"></p></div>
                                <div><p class="font-bold text-gray-600">2031</p><p id="tdoc-2031" class="font-mono mt-1 font-bold"></p></div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </section>

        <!-- Key Risks Section -->
        <section class="my-16">
            <div class="max-w-6xl mx-auto">
                <h2 class="font-heading text-3xl md:text-4xl font-bold text-primary text-center mb-12">Navigating the Headwinds: Key Risks</h2>
                <div class="grid grid-cols-1 md:grid-cols-2 gap-8">
                    <div class="bg-accent p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-3">Government-Led Price Controls</h3>
                        <p class="text-gray-600">The single largest threat. Faced with budget pressure, governments may enact legislation that directly controls drug and device prices, severely compressing profitability for innovative companies.</p>
                    </div>
                    <div class="bg-accent p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-3">Pivotal Clinical Trial Failure</h3>
                        <p class="text-gray-600">A high-profile, late-stage clinical trial failure for a key pipeline asset could wipe out a significant portion of a company's future growth prospects and market valuation.</p>
                    </div>
                    <div class="bg-accent p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-3">Disruptive New Entrant / Technology</h3>
                        <p class="text-gray-600">A well-funded competitor (including Big Tech) could launch a technologically superior or lower-cost product that renders an incumbent's platform obsolete, leading to rapid market share loss.</p>
                    </div>
                     <div class="bg-accent p-8 rounded-2xl border border-gray-200">
                        <h3 class="font-heading text-xl font-bold text-primary mb-3">Failure to Secure Reimbursement</h3>
                        <p class="text-gray-600">A novel technology may receive regulatory approval but fail to secure broad coverage from major payers (e.g., Medicare), severely limiting its commercial potential and path to profitability.</p>
                    </div>
                </div>
            </div>
        </section>

        <!-- Footer -->
        <footer class="text-center my-16 pt-8 border-t border-gray-200">
            <p class="text-sm text-gray-500 max-w-4xl mx-auto">
                Disclaimer: This information is for informational purposes only and does not constitute financial advice. All investment strategies and investments involve risk of loss. Please conduct your own research and consult with a financial professional before making any investment decisions.
            </p>
        </footer>

    </div>

    <script>
        document.addEventListener('DOMContentLoaded', function () {
            const performanceDrivers = {
                bear: {
                    vrtx: `<span class="negative-driver">- Negative pricing legislation severely impacts CF franchise profitability.</span><br><span class="negative-driver">- Key pipeline assets outside of CF face clinical or regulatory setbacks.</span>`,
                    isrg: `<span class="negative-driver">- Procedure growth falls to low single-digits due to budget cuts and competition.</span><br><span class="negative-driver">- Margin erosion from low-cost competitors.</span>`,
                    gh: `<span class="negative-driver">- CMS issues a negative national coverage decision for Shield screening test.</span><br><span class="negative-driver">- Fails to reach profitability, requiring dilutive financing.</span>`,
                    tdoc: `<span class="negative-driver">- Market commoditization and intense competition prevent a return to meaningful growth.</span><br><span class="negative-driver">- Fails to achieve sustained profitability.</span>`
                },
                neutral: {
                    vrtx: `<span class="positive-driver">+ Successful launch of one new blockbuster drug outside of CF franchise.</span><br><span>+ Continued market dominance and penetration in core CF market.</span>`,
                    isrg: `<span class="positive-driver">+ Maintains market leadership and mid-teens procedure growth despite new entrants.</span><br><span>+ Successful adoption cycle of new da Vinci 5 system.</span>`,
                    gh: `<span class="positive-driver">+ Achieves corporate profitability by 2028 target.</span><br><span>+ Shield test gains traction and secures broader payer coverage.</span>`,
                    tdoc: `<span>- Achieves sustained low single-digit growth and steady margin expansion.</span><br><span>- Successful integration of assets leads to improved operating leverage.</span>`
                },
                bull: {
                    vrtx: `<span class="positive-driver">+ R&D pipeline delivers multiple new blockbuster therapies in different disease areas.</span><br><span class="positive-driver">+ Gene therapies prove to be durable cures, establishing a new high-margin platform.</span>`,
                    isrg: `<span class="positive-driver">+ Next-gen platforms enable new categories of automated procedures, expanding TAM.</span><br><span class="positive-driver">+ Becomes undisputed standard of care across most major surgical specialties.</span>`,
                    gh: `<span class="positive-driver">+ Shield becomes the standard of care for screening multiple cancer types.</span><br><span class="positive-driver">+ Data asset becomes a highly valuable source of recurring revenue.</span>`,
                    tdoc: `<span class="positive-driver">+ Virtual-first models become the dominant form of delivery for primary and chronic care.</span><br><span class="positive-driver">+ Becomes the default, integrated "front door" to the healthcare system.</span>`
                }
            };

            const performanceFigures = {
                bear: {
                    vrtx: [2, 1, 0, -1, -2, 0, 0],
                    isrg: [-2, -4, -6, -8, -5, -3, -2],
                    gh: [-15, -20, -25, -30, -20, -15, -15],
                    tdoc: [-8, -10, -12, -15, -10, -8, -7]
                },
                neutral: {
                    vrtx: [10, 11, 12, 13, 14, 12, 12],
                    isrg: [8, 9, 10, 11, 12, 10, 10],
                    gh: [5, 10, 15, 20, 25, 15, 15],
                    tdoc: [2, 4, 6, 8, 10, 12, 14]
                },
                bull: {
                    vrtx: [15, 18, 20, 22, 25, 20, 20],
                    isrg: [12, 15, 18, 20, 22, 19, 18],
                    gh: [20, 25, 30, 40, 50, 35, 30],
                    tdoc: [10, 15, 20, 25, 30, 35, 40]
                }
            };

            const scenarioControls = document.getElementById('scenario-controls');
            const buttons = scenarioControls.querySelectorAll('.scenario-btn');
            
            const descriptionContainer = document.getElementById('scenario-descriptions');
            const allDescriptions = descriptionContainer.querySelectorAll('.scenario-desc');
            
            const elements = {
                vrtx: document.getElementById('vrtx-drivers'),
                isrg: document.getElementById('isrg-drivers'),
                gh: document.getElementById('gh-drivers'),
                tdoc: document.getElementById('tdoc-drivers'),
            };

            function updateDisplay(scenario) {
                // Update performance drivers
                for (const asset in performanceDrivers[scenario]) {
                    if (elements[asset]) {
                        elements[asset].innerHTML = performanceDrivers[scenario][asset];
                    }
                }

                // Update performance figures
                const years = [2025, 2026, 2027, 2028, 2029, 2030, 2031];
                for (const asset in performanceFigures[scenario]) {
                    const yearlyReturns = performanceFigures[scenario][asset];
                    yearlyReturns.forEach((value, index) => {
                        const year = years[index];
                        const el = document.getElementById(`${asset}-${year}`);
                        if (el) {
                            const sign = value >= 0 ? '+' : '';
                            el.textContent = `${sign}${value}%`;
                            el.classList.remove('positive-driver', 'negative-driver');
                            if (value >= 0) {
                                el.classList.add('positive-driver');
                            } else {
                                el.classList.add('negative-driver');
                            }
                        }
                    });
                }
                
                // Update descriptions
                allDescriptions.forEach(desc => desc.classList.add('hidden'));
                const activeDesc = document.getElementById(`desc-${scenario}`);
                if(activeDesc) {
                    activeDesc.classList.remove('hidden');
                }
            }

            scenarioControls.addEventListener('click', (event) => {
                const target = event.target.closest('.scenario-btn');
                if (!target) return;

                buttons.forEach(btn => btn.classList.remove('active'));
                target.classList.add('active');
                
                const scenario = target.dataset.scenario;
                updateDisplay(scenario);
            });

            // Initial load
            updateDisplay('neutral');
        });
    </script>

</body>
</html>

